Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Products of conception

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7382   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    40 result(s) found for: Products of conception. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2018-001187-33 Sponsor Protocol Number: APD811-301 Start Date*: 2019-02-12
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HR (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001950-16 Sponsor Protocol Number: ISI-2015-1 Start Date*: 2017-03-03
    Sponsor Name:Isifer AB
    Full Title: A randomized, double blind, controlled, parallel group, multi-centre phase II clinical study of lidocaine pertubation as a treatment for couples with unexplained infertility
    Medical condition: Unexplained infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001189-40 Sponsor Protocol Number: APD811-303 Start Date*: 2023-04-05
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION
    Medical condition: Pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) SE (Prematurely Ended) GB (GB - no longer in EU/EEA) CZ (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) HR (Completed) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-001555-37 Sponsor Protocol Number: CC-10004-AS-001 Start Date*: 2012-09-04
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of apremilast (CC-10004) in the treatment of active ankylosing spondyl...
    Medical condition: Ankylosing spondylitis (AS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002556 Ankylosing spondylitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) SK (Completed) NL (Completed) ES (Completed) PL (Completed) SE (Completed) CZ (Completed) AT (Completed) BG (Completed) FR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022103-21 Sponsor Protocol Number: TUE-002 Start Date*: 2011-04-08
    Sponsor Name:University Hospital Tübingen
    Full Title: Neoadjuvant treatment of locoregional metastases in malignant melanoma (AJCC stage IIIB/C) with Multiferon: a phase IIa DeCOG trial
    Medical condition: The study is an open label, multicenter phase IIa clinical trial which is designed as a pilot project in order to establish the efficacy and tolerability of Multiferon as a neoadjuvant treatment o...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005068-29 Sponsor Protocol Number: C2006-01 Start Date*: Information not available in EudraCT
    Sponsor Name:A.P. Pharma, Inc.
    Full Title: A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi® for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea a...
    Medical condition: Chemotherapy Induced Nausea and Vomiting
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054133 Prophylaxis of nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001554-10 Sponsor Protocol Number: NL57892 Start Date*: 2016-06-21
    Sponsor Name:Radboudumc
    Full Title: Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: a pilot study
    Medical condition: Women aged above 18 years with early pregnancy failure, 6-14 weeks postmenstrual.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10068522 Non-surgical treatment LLT
    19.0 100000004868 10027650 Miscarriage of pregnancy LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004454-33 Sponsor Protocol Number: EMR 062 240-506 Start Date*: 2009-01-21
    Sponsor Name:Merck KGaA
    Full Title: Open, randomized, multinational phase IIIb trial evaluating the activity and safety of cetuximab as 250 mg/m² weekly and 500 mg/m² every two weeks maintenance therapy after platinum-based chemother...
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) HU (Completed) SK (Completed) FR (Completed) AT (Prematurely Ended) ES (Completed) IT (Completed) GR (Completed) PL (Completed) GB (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003711-21 Sponsor Protocol Number: MS100070_0176 Start Date*: 2019-08-29
    Sponsor Name:Merck KGaA
    Full Title: An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) CZ (Completed) HU (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002942-30 Sponsor Protocol Number: 01012015 Start Date*: 2015-12-10
    Sponsor Name:Regional Hospital of Randers
    Full Title: CONDISOX: Continued versus discontinued oxytocin stimulation of labour in a double-blind randomised controlled trial
    Medical condition: Syntocinon is used for labour induction to stimulate contractions. The current recommendation is to stimulate until delivery. We hypothesize that discontinuation of Syntocinon when the active phase...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10062462 Labor stimulation LLT
    20.0 100000004868 10023540 Labor induced LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003697-70 Sponsor Protocol Number: VIB4920.P2.S3 Start Date*: 2020-02-21
    Sponsor Name:Viela Bio, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Mechanistic Insight and Dosage Optimization Study of the Efficacy and Safety of VIB4920 in Patients with Rheumatoid Arthritis (RA)
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-020324-22 Sponsor Protocol Number: CC-10004-PSA-005 Start Date*: 2011-03-07
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who...
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6 to 39% of patients with psoriasis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed) CZ (Completed) LT (Completed) IT (Completed) PL (Completed) BG (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018386-32 Sponsor Protocol Number: CC-10004-PSA-003 Start Date*: 2010-12-27
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) EE (Completed) GB (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-001132-22 Sponsor Protocol Number: GEM-1202 Start Date*: 2014-02-24
    Sponsor Name:Grupo Español Multidisciplinar de Melanoma
    Full Title: A MULTICENTER, SINGLE ARM, PHASE 2 CLINICAL STUDY ON THE COMBINATION OF RADIATION THERAPY AND IPILIMUMAB, FOR THE TREATMENT OF PATIENTS WITH MELANOMA AND BRAIN METASTASES.
    Medical condition: Patients with melanoma and brain metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023058-35 Sponsor Protocol Number: UZB-VUB-10-001 Start Date*: 2011-01-04
    Sponsor Name:UZ BRUSSEL
    Full Title: A Two-Stage Phase II Study of Autologous TriMix-DC Therapeutic Vaccine in Combination with Ipilimumab in Patients with Previously Treated Unresectable Stage III or IV Melanoma
    Medical condition: Previously Treated Unresectable Stage III or IV Melanoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025670 Malignant melanoma stage III LLT
    12.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003309-88 Sponsor Protocol Number: ROR-PH-302 Start Date*: 2020-06-02
    Sponsor Name:United Therapeutics Corporation
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World He...
    Medical condition: pulmonary arterial hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Prematurely Ended) ES (Ongoing) PL (Prematurely Ended) BE (Completed) IT (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021946-22 Sponsor Protocol Number: DeCOG–MM-PAL11 Start Date*: 2011-04-05
    Sponsor Name:University Hospital Essen
    Full Title: THE IPI – MULTIBASKET TRIAL IN ADVANCED OCULAR MELANOMA: PROSPECTIVE CLINICAL PHASE II MULTIBASKET STUDY IN OCULAR MELANOMA PATIENTS WITH ADVANCED DISEASE
    Medical condition: Histologically proven uveal melanoma Measurable disease according to RECIST in unresectable stage III-IV
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068117 Metastatic ocular melanoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005282-12 Sponsor Protocol Number: Start Date*: 2013-05-14
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. Research and Development NHS Lothian
    Full Title: TOFFEE Trial Toxicity OF Fluoropyrimidines: A comparative study of the cardiotoxicity of capEcitabine and tEysuno
    Medical condition: All gastrointestinal and hepatobiliary cancers including colorectal cancer, cancer of unknown primary, pancreatic cancer, stomach cancer and oesophageal cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004212-21 Sponsor Protocol Number: AMAG-423-201 Start Date*: 2019-05-24
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree...
    Medical condition: Severe Preeclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Prematurely Ended) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009856-19 Sponsor Protocol Number: 42160443PAI2004AmINT-2 Start Date*: 2009-12-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 as Adjunctive Therapy in Subjects With Moderate to Severe Knee ...
    Medical condition: moderate to severe, chronic, knee or hip pain from osteoarthritis (OA) that is not adequately controlled by standard pain therapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10023477 Knee pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Oct 22 07:35:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA